The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Biologic and clinical progression in hematological malignancies at ASH 2020
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the developments in hematological malignancies seen at ASH 2020. With the use of single-cell mutational analysis and epigenomics tools, there is an increasing understanding of the mechanisms of disease progression and evolution. As well as this, clinical advancements have been made in every major disease area, with growing use of novel agents and new drug combinations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
